LONDON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration ...
Application of the integrated TxPro + CipherPro platform revealed a marked increase in predicted tumour-selective opportunities across multiple selection criteria. Using a DE threshold greater than 10 ...
LONDON--(BUSINESS WIRE)--ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of ...
Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026 Scarcity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results